Company Performance Metrics
Attilio Di Fiore: CTO, COO- Angus Jackson: Director of Corporate DevelopmentPast Role: Adventa Bioscience, CBO
ATTWILL was founded in 2013 with the mission "to end catheter related failures in vascular access, and to improve patient quality of life while undergoing treatment using a catheter".
ATTWILL is engaged in the development and evaluation of new IP, and the design of innovative excellent accessory products that can improve both treatment
and patient outcomes by significantly reducing the complications caused by vascular access devices.
ATTWILL has filed 8 patents on two technologies and has one patent issued for a core technology. The two core vascular access technologies are novel devices. One device sterilizes the inner lumen of devices. CHGLock is a connector device for delivering Chlorhexdine (antimicrobial) into the lumen of catheters during the locking of catheters. Its goal is to eliminate bacteria inside catheters. ATHLock is a connector device that delivers novel antithrombin and heparin (anticoagulant) into the inner lumen of catheters during the locking of catheters. The goal of ATHLock is to prevent blood clots inside the catheters. These two technologies have been licensed to ICU Medical Inc. for world wide distribution. ICU Medical is the market leader in catheter connector valve technologies. ICU is a NASDAQ listed company.
ATH is a platform technology that can be used where heparin is currently being used as an anticoagulant. It can be applied as a coating to devices, such as catheters and VADs (ventricular assist devices) where blood clotting on the device is potentially harmful to the patient.
In the October of 2017, ATTWILL Vascular purchased the industry-leading facilities of Anteco Pharma and launched ATTWILL Medical Solutions specializing in the lyophilization and related processing of pharmaceutical intermediates, medical devices and specialty food and nutritional ingredients.
